PDCD1 and hepatocellular carcinoma: In HCC patients treated with anti-PD-1 monoclonal antibodies, the PNI decreased in the progressive disease (PD) group after treatment compared to the non-PD group(P = 0.023), and an increased PNI was associated with longer OS (P = 0.014) (53).